Nebulizers - Final LCD and Response to Comments (RTC) Article Published - JA DME
Nebulizers - Final LCD and Response to Comments (RTC) Article Published
Joint DME MAC Publication
December 18, 2025
On December 18, 2025, the DME MACs published the following final Local Coverage Determination (LCD) and LCD-related Policy Article (PA):
- Nebulizers LCD (L33370) and LCD-related PA (A52466)
The LCD incorporates finalized revisions, as a result of the LCD reconsideration process and written comments received during the comment period for the proposed LCD. The final LCD adds coverage for the use of ensifentrine (J7601) as add-on therapy as part of a maintenance regimen that includes dual long-acting beta-agonist (LABA) + long-acting muscarinic-agonist (LAMA) therapy with or without an inhaled corticosteroid; and, adds coverage for the use of hypertonic saline (J7131) for the management of cystic fibrosis, non-cystic fibrosis bronchiectasis and primary ciliary dyskinesia.
The posting of the final LCD marks the beginning of the 45-day notice period. The final LCD goes into effect for claims with dates of service on or after February 1, 2026.
Along with the final LCD and LCD-related PA, the DME MACs published a Response to Comments (RTC) Article which addresses the written comments received during the comment period. The RTC Article is as follows:
- Response to Comments: Nebulizers - DL33370 (A60378)
Interested stakeholders may find the RTC document by searching for the article number in the Medicare Coverage Database. The RTC document is also located in the Associated Documents section of the LCD.
Please refer to each DME MAC website for additional information about policy development and access to the final LCD.
